The implantable left ventricular assist device, named HeartCon or “rocket heart” and independently developed and produced by Rocor Medical Technology Co, was approved by the National Medical Products Administration to enter the market tomorrow.
In addition, the device was the first domestically made artificial heart in China to have successfully completed 50 cases of clinical trials and fully meet the clinical trial requirements and regulations set by the administration, TEDA International Cardiovascular Hospital in Tianjin said in a news release.
“This purely domestic artificial heart is expected to end the story that China is unable to treat advanced heart failure, and is good news for Chinese patients with severe heart failure,” Liu said.